{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:48:40Z","timestamp":1740134920241,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,14]]},"DOI":"10.1182\/blood.2023021284","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:53:57Z","timestamp":1694706837000},"page":"941-943","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["CLL patients: GIVe me three!"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-5079","authenticated-orcid":false,"given":"Marwan","family":"Kwok","sequence":"first","affiliation":[{"name":"1University of Birmingham"},{"name":"2Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-274X","authenticated-orcid":false,"given":"Tatjana","family":"Stankovic","sequence":"additional","affiliation":[{"name":"1University of Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"11","key":"2023091415341335200_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final\u00a0analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"31","key":"2023091415341335200_bib2","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-na\u00efve and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023091415341335200_bib3","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"2023091415341335200_bib4","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023091415341335200_bib5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2021013208","article-title":"Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia","volume":"139","author":"Huber","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023091415341335200_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2022-168003","article-title":"Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2023091415341335200_bib7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 16","key":"2023091415341335200_bib8","article-title":"Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)","volume":"41","author":"Yin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023091415341335200_bib9","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7762","key":"2023091415341335200_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","article-title":"Growth dynamics in naturally progressing chronic lymphocytic leukaemia","volume":"570","author":"Gruber","year":"2019","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/11\/941\/2076459\/blood_bld-2023-021284-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/11\/941\/2076459\/blood_bld-2023-021284-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:54:07Z","timestamp":1694706847000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/11\/941\/497754\/CLL-patients-GIVe-me-three"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021284","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}